Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Sees Large Decline in Short Interest

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) saw a significant decline in short interest in February. As of February 13th, there was short interest totaling 20,230 shares, a decline of 67.0% from the January 29th total of 61,344 shares. Approximately 3.0% of the company’s stock are short sold. Based on an average trading volume of 466,445 shares, the short-interest ratio is presently 0.0 days. Based on an average trading volume of 466,445 shares, the short-interest ratio is presently 0.0 days. Approximately 3.0% of the company’s stock are short sold.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on BDRX shares. Wall Street Zen raised Biodexa Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, February 22nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Institutional Investors Weigh In On Biodexa Pharmaceuticals

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Armistice Capital LLC bought a new stake in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned about 14.71% of Biodexa Pharmaceuticals at the end of the most recent quarter. Institutional investors own 17.51% of the company’s stock.

Biodexa Pharmaceuticals Stock Performance

Shares of BDRX traded down $0.04 on Friday, reaching $1.10. 21,411 shares of the stock traded hands, compared to its average volume of 353,369. Biodexa Pharmaceuticals has a 12 month low of $1.04 and a 12 month high of $44.40. The stock’s 50-day moving average price is $1.96 and its 200-day moving average price is $4.70.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.